Houston Oncology Summit: Oppenheimer analyst Matthew Biegler talks about synthetic lethality
He describes how PARP inhibitors were initial successes and where the field is going now beyond PARP with new targets.
Brought to you by:
top of page
Follow BiotechTV
Also look for unique social pages for BiotechTV U.
Popular
#1. Pfizer’s CEO on Q2 earnings.
​
#2. Moderna CEO Stéphane Bancel on Moderna’s business at its R&D Day in New York
​
#3. UPenn’s Bruce Levine discusses the progress of CAR-T
​
#4. Learning about gene writing at Tessera Therapeutics
#5. Visiting Bayer’s Research and Innovation Center in Kendall Square
bottom of page